MALDI Biotyper

Trade Agreement: WTO-AGP/NAFTA/AIT/Canada FTAs with Peru/Colombia/Panama Tendering Procedures: Generally only one firm has been invited to bid Attachment: None Non-Competitive Procurement Strategy: Exclusive Rights Comprehensive Land Claim Agreement: No Vendor Name and Address: BRUKER LTD. 555 Steeles Ave East Milton Ontario Canada L9T1Y6 Nature of Requirements: MALDI Biotyper-CM

6D063-132573/A Tammy Kozak Telephone No. - (204) 984-8825 Fax No. - (204) 983-7796

1. INTRODUCTION Public Works and Government Services Canada (PWGSC), on behalf of the National Microbiology Laboratory (NML), intends to solicit a proposal and negotiate a contract with Bruker Ltd. In Milton, Ontario for the supply and installation of a MALDI Biotyper-CM.

2. BACKGROUND The National Microbiology Laboratory (NML), a directorate of the Infectious Disease and Emergency Preparedness Branch, Public Health Agency of Canada (PHAC), is located in the Canadian Science Centre for Human and Animal Health (CSCHAH) in Winnipeg, Manitoba.

As Canada's leading public health infectious disease laboratory, the NML is responsible for the identification, control and prevention of infectious diseases. The NML's activities include reference microbiology, support to epidemiology programs, surveillance, emergency response, applied and discovery research, and management of intellectual assets to improve public health in Canada and internationally.

The Bioforensics Assay Development and Diagnostics (BADD) group of the NML (PHAC) is responsible for the Government of Canada's bioterrorism (BT) response capacity and is a part of the National CBRNE team under mandate of the Federal Emergency Management Act & the Federal Emergency Response Plan. The BADD group performs diagnostic testing of all Category A- list bioterrorism agents and leads the microbial forensics team for trace-attribution of a biocrime. In the event of a microbiological emergency, the BADD team is able to deploy to the site of the event and test biological samples directly on-site for infectious agents or toxins.

3. REQUIREMENT The NML requires cutting-edge instruments for the detection and identification of BT agents by their unique protein profile. Specifically this instrument is for analysis of bacterial cultures and diagnostic samples in our BSL-2 (biosafety level 2) and BSL-3 containment laboratories, as well as the mobile laboratory truck. A sensitive instrument for the analysis of bacterial cultures is the Bruker Ltd. Microflex LT MALDI-TOF (matrix-assisted laser desorption/ionization) mass spectrometer (MS), which can fit on a laboratory bench-top. This instrument produces unique bacterial protein spectra, allowing bacterial identification against a database of known spectra. Furthermore, it is compatible with currently-used bacterial identification databases at the NML. Therefore, by acquiring the Bruker MALDI-TOF Microflex LT the NML will increase its capacity for rapid BT agent identification.

Also, this technology anticipates the coordination diagnostic capabilities between the NML and the Canadian Laboratory Response Network (CLRN), a group of Canadian public health laboratories who are accredited for testing suspected BT agents. This cooperation will expand the coordination and response capability to microbiological emergencies across Canada.

4. MANDATORY PERFORMANCE SPECIFICATIONS Any interested supplier must demonstrate by way of a statement of capabilities that its system meets the following mandatory requirements: 1) MALDI-TOF based mass spectrometry for analysis of bacterial samples. 2) Due to the requirement for fitting into our unique CL-3 laboratory with limited space, must be a compact, bench-top size instrument no larger than 25 inches x 30 inches x 50 inches (height), and a reasonable weight (